Literature DB >> 16481805

Planned post-chemoradiation neck dissection: significance of radiation dose.

Kerstin M Stenson1, Dezheng Huo, Elizabeth Blair, Ezra E W Cohen, Athanassios Argiris, Daniel J Haraf, E Everett Vokes.   

Abstract

OBJECTIVE: The increasing prominence of multimodality therapy for patients with advanced head and neck cancer reflects its high survival and functional preservation rates. We report the pathologic data on patients undergoing neck dissection (ND) after induction chemotherapy followed by concomitant chemoradiotherapy (IC-CRT) in three similar protocols utilizing decreasing doses of radiation therapy.
MATERIALS AND METHODS: The databases of 221 patients who underwent IC-CRT between 1999 and 2002 were reviewed. Based on posttreatment residual or pretreatment N2a or greater neck disease, 73 patients without pretreatment neck surgery were eligible for analysis (1 N1, 3 N2a, 26 N2b, 20 N2c, 23 N3). Three additional subgroups were also analyzed with respect to outcome: Undissected patients with less than N2 disease, patients who had neck surgery prior to IC-CRT, and patients with N2a or greater neck disease who did not have post-IC-CRT ND. STUDY
DESIGN: Retrospective analysis.
RESULTS: Sixty-seven patients underwent unilateral or bilateral selective neck dissection. Six patients had modified or radical ND. There were no wound healing complications. Pathologic analysis revealed viable cancer in 15 of 73 patients (20.5%): 1 had N1, 3 had N2b, 4 had N2c, and 7 had N3 neck disease. The incidence of viable cancer in the neck dissection specimen increased as radiation dose decreased. Complete response induction chemotherapy predicted negative pathology (P = .003). In the subgroup analysis, patients who had pretreatment surgery had a lower risk of dying from the primary cancer
CONCLUSIONS: 1) The incidence of positive pathology after IC-CRT increases as radiation dose decreases. 2) Selective neck dissection after CRT has been demonstrated to be feasible and safe; the complication rate of ND after IC-CRT is acceptably low. 3) There is viable posttreatment cancer in 20.5% of patients, indicating necessity of ND in these patients.

Entities:  

Mesh:

Year:  2006        PMID: 16481805     DOI: 10.1097/01.mlg.0000185846.27617.fe

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  9 in total

1.  Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancer.

Authors:  Peter A Paximadis; Michael E Christensen; Greg Dyson; Dev P Kamdar; Ammar Sukari; Ho-Sheng Lin; George H Yoo; Harold E Kim
Journal:  Head Neck       Date:  2012-02-06       Impact factor: 3.147

2.  Radical neck dissection: is it still indicated?

Authors:  Marc Hamoir; Carl E Silver; Sandra Schmitz; Robert P Takes; Alessandra Rinaldo; Juan P Rodrigo; K Thomas Robbins; Karen T Pitman; Jesus E Medina; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-30       Impact factor: 2.503

3.  Neck dissection after chemoradiotherapy for oropharyngeal and hypopharyngeal cancer: the correlation between cervical lymph node metastasis and prognosis.

Authors:  Nobuhiro Hanai; Daisuke Kawakita; Taijiro Ozawa; Hitoshi Hirakawa; Takeshi Kodaira; Yasuhisa Hasegawa
Journal:  Int J Clin Oncol       Date:  2013-01-23       Impact factor: 3.402

Review 4.  Efficacy of neck dissection in the management of isolated nodal recurrence after head and neck cancer treatment.

Authors:  Jimmy Yu-wai Chan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

Review 5.  The role of neck dissection in squamous cell carcinoma of the head and neck.

Authors:  Marc Hamoir; Sandra Schmitz; Vincent Gregoire
Journal:  Curr Treat Options Oncol       Date:  2014-12

6.  Hyperfractionated radiotherapy with concurrent cisplatin/5-Fluorouracil for locoregional advanced head and neck cancer: analysis of 105 consecutive patients.

Authors:  David Zaboli; Marietta Tan; Hrishikesh Gogineni; Spencer Lake; Katherine Fan; Marianna L Zahurak; Barbara Messing; Karen Ulmer; Eva S Zinreich; Marshall A Levine; Mei Tang; Sara I Pai; Ray G Blanco; John R Saunders; Simon R Best; Joseph A Califano; Patrick K Ha
Journal:  Int J Otolaryngol       Date:  2012-06-21

Review 7.  Advances in the management of squamous cell carcinoma of the head and neck.

Authors:  Jean-Pascal Machiels; Maarten Lambrecht; François-Xavier Hanin; Thierry Duprez; Vincent Gregoire; Sandra Schmitz; Marc Hamoir
Journal:  F1000Prime Rep       Date:  2014-06-02

8.  Prediction of concurrent chemoradiotherapy outcome in advanced oropharyngeal cancer.

Authors:  Masahiro Hasegawa; Hiroyuki Maeda; Zeyi Deng; Asanori Kiyuna; Akira Ganaha; Yukashi Yamashita; Sen Matayoshi; Shinya Agena; Takafumi Toita; Takayuki Uehara; Mikio Suzuki
Journal:  Int J Oncol       Date:  2014-06-18       Impact factor: 5.650

9.  Complete pathologic response as a prognostic factor for squamous cell carcinoma of the oropharynx post-chemoradiotherapy.

Authors:  Damila Cristina Trufelli; Leandro Luongo de Matos; Thaiana Aragão Santana; Fábio de Aquino Capelli; Jossi Ledo Kanda; Auro Del Giglio; Gilberto de Castro Junior
Journal:  Braz J Otorhinolaryngol       Date:  2015-07-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.